The Effects of Ketogenic Diet and Calorie-Restricted Diet on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Study

Why It Matters

The findings suggest KD can accelerate liver‑fat reduction and insulin improvement in MASLD beyond weight loss alone, offering a potent dietary option. However, the associated muscle loss highlights the need for adjunctive strategies to preserve lean mass.

Key Takeaways

• KD cut hepatic fat (CAP) by 62 dB/m vs 36 dB/m for CRD
• 84% of KD patients achieved ≥40 dB/m CAP reduction, vs 45% on CRD
• KD led to greater muscle loss (3 kg) compared with CRD (1.8 kg)
• Both diets improved liver stiffness, but between‑group difference was not significant
• KD reduced fasting insulin more than CRD, significance vanished after adjustment

Pulse Analysis

Metabolic dysfunction‑associated steatotic liver disease (MASLD) now affects roughly one‑third of adults worldwide, yet no pharmacologic therapy has secured regulatory approval. Clinicians therefore lean heavily on lifestyle interventions, with dietary modification at the forefront. Recent guidelines have begun to acknowledge low‑carbohydrate, high‑fat regimens as a plausible option, but robust comparative data remain scarce. This study adds a sizable real‑world cohort that directly pits a ketogenic diet against a conventional calorie‑restricted plan, offering fresh insight into how macronutrient composition influences liver fat beyond simple caloric deficit.

The KD’s superiority in reducing controlled attenuation parameter (CAP) by an average of 62 dB/m underscores the metabolic advantage of severe carbohydrate restriction. By sharply lowering insulin levels, the diet curtails de novo lipogenesis and promotes hepatic fatty‑acid oxidation, mechanisms that can shrink liver fat even before substantial weight loss occurs. However, the pronounced loss of lean muscle—approximately 3 kg versus 1.8 kg with CRD—raises a red flag for long‑term metabolic health, as skeletal muscle is a key glucose sink. Integrating resistance training and ensuring adequate protein intake could mitigate this downside, aligning the diet with a more holistic, muscle‑preserving approach.

From an industry perspective, these results could reshape nutrition‑focused therapeutic strategies for MASLD. Health insurers and employer wellness programs may begin to favor structured ketogenic protocols, especially if future randomized trials confirm durability and safety. Meanwhile, biotech firms developing anti‑fibrotic agents might consider combining pharmacotherapy with KD to accelerate steatosis resolution, potentially shortening trial timelines. The study also highlights the need for personalized nutrition platforms that monitor body‑composition metrics, ensuring patients reap hepatic benefits without sacrificing muscle mass. As evidence accumulates, KD could move from a niche weight‑loss fad to a mainstream component of MASLD management guidelines.